KALA BIO, Inc.
About KALA BIO, Inc.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2017
- $0
- Net income
- -$27.0M
- Total assets
- $9.5M
- Market cap
- $38.3M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $39.2M
- Operating income
- -$39.2M
- Income tax
- $0
- Net income
- -$27.0M
- EPS (basic)
- $-3.31
- EPS (diluted)
- $-3.31
Balance sheet
- Total assets
- $9.5M
- Current assets
- $9.5M
- Total liabilities
- $2.5M
- Current liabilities
- $2.5M
- Shareholders’ equity
- $7.0M
Cash flow
- Operating cash flow
- -$32.0M
- Investing cash flow
- -$15.0K
- Financing cash flow
- -$11.6M
- Net cash flow
- -$43.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $38.3M
- EPS (diluted)
- $-3.31
- Shares outstanding
- 16.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 20, 2017
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $27.0M in FY2017.
- Trading 100% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review KALA BIO, Inc..
Write a review
News about KALA BIO, Inc.
News & sentiment via Polygon.io
